Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last SFr.32.80 CHF
Change Today -0.85 / -2.53%
Volume 850.0
PFE On Other Exchanges
Symbol
Exchange
New York
Xetra
Mexico
SIX Swiss Ex
Stockholm
London
Sao Paulo
Bogota
As of 6:24 AM 04/28/15 All times are local (Market data is delayed by at least 15 minutes).

pfizer inc (PFE) Snapshot

Open
SFr.33.14
Previous Close
SFr.33.65
Day High
SFr.32.80
Day Low
SFr.32.80
52 Week High
03/16/15 - SFr.34.72
52 Week Low
08/8/14 - SFr.25.40
Market Cap
201.4B
Average Volume 10 Days
2.4K
EPS TTM
--
Shares Outstanding
6.1B
EX-Date
05/6/15
P/E TM
--
Dividend
SFr.1.12
Dividend Yield
2.97%
Current Stock Chart for PFIZER INC (PFE)

pfizer inc (PFE) Details

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments. The GIP segment develops, registers, and commercializes medicines for various therapeutic areas, including inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases, and women’s/men’s health. The VOC segment develops and commercializes vaccines, as well as products for oncology. It also provides over-the-counter products comprising dietary supplements under the Centrum, Caltrate, and Emergen-C brands; pain management products under the Advil and ThermaCare brands; gastrointestinal products under the Nexium 24HR/Nexium Control brand; respiratory products under the brand names of Robitussin, Advil Cold & Sinus, Advil Congestion Relief, and Dimetapp; and personal care products under the ChapStick and Preparation H brands. The GEP segment offers patent-protected products that have lost marketing exclusivity in various markets; and generic pharmaceuticals, and sterile injectable and biosimilar development products. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. It has collaboration with BIND Therapeutics, Inc. to develop and commercialize multiple Accurins. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

78,300 Employees
Last Reported Date: 02/27/15
Founded in 1849

pfizer inc (PFE) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.8M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $1.3M
President of Worldwide Research & Development
Total Annual Compensation: $1.2M
Group President of Global Innovative Pharma B...
Total Annual Compensation: $1.2M
Group President of Global Established Pharma ...
Total Annual Compensation: $1.0M
Compensation as of Fiscal Year 2014.

pfizer inc (PFE) Key Developments

Pfizer Inc. Declares Dividend for Second-Quarter 2015, Payable on June 2, 2015

The board of directors of Pfizer Inc. declared a 28-cent second-quarter 2015 dividend on the company’s common stock, payable June 2, 2015, to shareholders of record at the close of business on May 8, 2015.

Pfizer Inc. Presents at Milken Institute, Global Conference 2015, Apr-27-2015 03:45 PM

Pfizer Inc. Presents at Milken Institute, Global Conference 2015, Apr-27-2015 03:45 PM. Venue: 2025 Ave Of The Stars, Los Angeles, CA 90067, California, United States. Speakers: Freda C. Lewis-Hall, Chief Medical Officer and Executive Vice President.

Pfizer Receives U.S. FDA Breakthrough Therapy Designation for XALKORI (Crizotinib) for the Treatment of Patients with ROS1-Positive Non-Small Cell Lung Cancer

Pfizer Inc. announced that XALKORI (crizotinib) received Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of patients with ROS1-positive non-small cell lung cancer (NSCLC). Occurring in approximately 1% of NSCLC cases, ROS1-positive NSCLC represents a particular molecular subgroup of NSCLC. XALKORI currently is approved in the U.S. for the treatment of patients with metastatic NSCLC whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. Enacted as part of the 2012 FDA Safety and Innovation Act (FDASIA), Breakthrough Therapy designation is intended to expedite the development and review of a potential new medicine if it is 'intended to treat a serious or life-threatening disease and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies. The Breakthrough Therapy designation is distinct from the FDA’s other mechanisms to expedite drug development and review. Pfizer will work closely with the FDA on the development of XALKORI for ROS1-positive NSCLC and provide the information needed to support a potential regulatory submission.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PFE:SW SFr.32.80 CHF -0.85

PFE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Merck & Co Inc $57.10 USD -0.50
Nestle SA SFr.74.90 CHF -0.10
Novartis AG SFr.99.15 CHF -1.25
Roche Holding AG SFr.274.20 CHF -4.60
Procter & Gamble Co/The $80.60 USD -0.40
View Industry Companies
 

Industry Analysis

PFE

Industry Average

Valuation PFE Industry Range
Price/Earnings 24.9x
Price/Sales 4.5x
Price/Book 3.1x
Price/Cash Flow 16.4x
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PFIZER INC, please visit www.pfizer.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.